Burlington, Ontario--(Newsfile Corp. - April 22, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company") announces, further to its news release dated March 13, 2026, that it is progressing towards completion of a non-brokered private placement (the "Offering") for up to $1,200,000 in gross proceeds, through the issuance of up to 40,000,000 units of the Company ("Units") at a price of $0.03 per Unit. Each Unit will consist of one (1) common share (a "Share") and one-half (1/2) of one common share purchase warrant (each whole warrant, a "Warrant"), with each Warrant being exercisable to purchase one additional Share at a price of $0.06 for twelve (12) months from the date of issuance.
The Company may pay finder's fees in connection with the Offering, as permitted by applicable securities laws and the rules of the Canadian Securities Exchange.
The Company intends to use the net proceeds from the Offering (a) to fund inventory production and (b) for general corporate purposes, excluding accrued salaries to officers or directors of the Company and payment for Investor Relations Activities (as such term is defined in the policies of the Canadian Securities Exchange).
The Offering is subject to execution of subscription agreements by the placees and to certain conditions including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange.
All securities issued in connection with the Offering will be subject to a four-month and one-day statutory resale restriction pursuant to applicable Canadian securities laws.
The securities being offered under the Offering have not been and will not be registered under the United States Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.
Share Cancellation Clarification
The Company also provides further clarification respecting its April 8, 2026 news release announcing the cancellation of 2 million common shares of the Company. In August 2024, pursuant to Promino's acquisition of Helios Helium Corp. ("Helios") by way of a three-cornered amalgamation, the Company indirectly acquired all of the investments owned by Helios, which included 2 million common shares of Promino itself. On April 1, 2026, following approval of the Company's board of directors, such shares were returned to treasury and subsequently cancelled, resulting in a 2 million share decrease in the number of issued outstanding common shares of the Company.
About Promino Nutritional Sciences Inc.
Promino Nutritional Sciences is a Canadian innovation company focused on science-based, clinically proven nutrition for muscle health and recovery. Its core product, Rejuvenate Muscle Health, is a clinically researched amino acid formula designed to rebuild, restore, and rejuvenate muscle tissue.
The Company also produces Promino - NSF Certified for Sport, trusted by elite athletes. Promino's ambassadors include Stanley Cup Champion Jack Eichel (Vegas Golden Knights) and MLB legend José Bautista.
Learn more at www.drinkpromino.com and www.rejuvenatemuscle.com.
Forward-Looking Statements
This news release contains forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipates", "expects" and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to the expectations of management regarding the proposed Offering, the expectations of management regarding the use of proceeds of the Offering, closing conditions for the Offering, the expiry of hold periods for securities distributed pursuant to the Offering, and Canadian Securities Exchange approval of the proposed Offering. All statements other than statements of historical fact, included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including that: the Company may not complete the Offering on terms favorable to the Company or at all; the Canadian Securities Exchange may not approve the Offering; the proceeds of the Offering may not be used as stated in this news release; the Company may be unable to satisfy all of the conditions to closing of the Offering; and those additional risks set out in the Company's public documents filed on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
For further information about Promino:
Moira Ong, CFO, mong@drinkpromino.com, 1-855-348-1970 (extension 204)
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293878
Source: Promino Nutritional Sciences, Inc.
